TB fight making progress, but more funds needed, WHO reports

by Naomi Seck

The war on tuberculosis is getting new weapons for the first time in decades, offering hope for controlling the deadly disease but major funding shortfalls threaten progress, the World Health Organization said Wednesday.

"We are at a crossroads between the elimination of TB within our lifetime, possibly, and millions of avoidable deaths in the next several years," Mario Raviglione, director of the WHO Stop TB Department emphasized at a press conference in Washington as the WHO released its annual report.

The choice, said Kenneth Castro, of the US Centers for Disease Control and Prevention, at the same press conference, is to "pay now, or pay more later."

The WHO has pledged to cut TB deaths to half the 1990 rate, a goal the agency said in its new report it was on track to achieve in most regions. The number of new cases per capita had also fallen—down 2.2 percent in 2011 from the year before.

Nevertheless, tuberculosis remains one of the world's top killers: in 2011, there were some 8.7 million new cases around the world, causing 1.4 million deaths, according to the new report.

And the epidemic of multi-drug-resistant tuberculosis remains a monumental challenge, Raviglione said.

In 2012, only about one in five of those estimated to have the TB strains resistant to standard medications were officially diagnosed as such, the report revealed. In China and India, that figure was even worse: fewer than one in 10 drug resistant cases were detected.

This is a critical problem, explained Anthony Fauci, director of the US National Institutes of Health allergy and infectious diseases arm, also at the press conference.

"One of the major reasons for the development of multiple-drug-resistant TB is inadequate treatment of plain old garden variety TB," Fauci told reporters.

"And one of the most important inciters of extensively drug resistant TB is inadequate treatment of multiple-drug-resistant TB."

But hope for wresting better control of the drug-resistant strains is rising thanks to a relatively new and inexpensive tool that allows for rapid diagnosis in a lab, in under two hours.

Some 67 developing countries, led by South Africa, are rolling out the molecular test, whose price has dropped by nearly half to $10 in the space of just a few months.

Equally exciting are two new drugs, on a path to be approved by the US and Europe for use in patients by next year.

The drugs—the first new TB medications in over forty years—were developed using high-tech analyses of the bacillus that causes tuberculosis, making them the first ever designed specifically for the treatment of the lung disease, he explained.

And as many as a dozen new vaccine candidates are in development to replace the imperfect one currently used.

Medical aid group Medicins Sans Frontiers agreed the new tools are promising, but said more must be done.

The WHO report "reinforces that multidrug-resistant tuberculosis is an escalating public health emergency," the group's TB advisor Grania Brigden said in a statement.

"Yet the global response is abysmal, with levels of testing and treatment remaining shockingly low," she said, adding that, even when diagnosed, the survival rate of multi-drug-resistant TB is less than 50 percent.

"We continue to struggle every day with inadequate tools and drugs to tackle the disease," which is increasing in prevalence in the places they work, she said.

Medical journal "The Lancet" was similarly frustrated, arguing in an editorial published to coincide with the WHO report that "insufficient attention and funding over several decades have allowed the global epidemic to remain a deep scar on the reputation of global health."

The WHO said it is $3 billion short of the $8 billion it needs to implement its plans to treat and control TB next year. And it has only a third of the $2 billion needed required for research and development.

"If the gaps are not filled ... we are going to see and we have to accept millions of deaths," from tuberculosis in the coming years, Raviglione warned.

"We will not have a decline in incidence. We will not be able to say elimination is possible in some settings, because the incidence will stabilize and probably grow again."

add to favorites email to friend print save as pdf

Related Stories

Tuberculosis cases decline worldwide: WHO

Oct 11, 2011

For the first time on record, fewer people worldwide are getting sick from tuberculosis, but cash is short in the fight against drug-resistant forms of the disease, the World Health Organization said Tuesday.

WHO: Money, drugs needed to rein in new TB strains

Mar 23, 2009

(AP) -- More money and better science are urgently needed to rein in new strains of tuberculosis that are tough or nearly impossible to treat, the WHO announced Monday in China, where the disease has long been a leading ...

Drug-resistant tuberculosis rife in China

Dec 11, 2008

Levels of drug-resistant tuberculosis (TB) in China are nearly twice the global average. Nationwide research published in the open access journal BMC Infectious Diseases has shown that almost 10% of Chinese TB cases are re ...

Recommended for you

Recorded Ebola deaths top 7,000

12 hours ago

The worst Ebola outbreak on record has now killed more than 7,000 people, with many of the latest deaths reported in Sierra Leone, the World Health Organization said as United Nations Secretary-General Ban ...

Liberia holds Senate vote amid Ebola fears (Update)

16 hours ago

Health workers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate election that has been criticized for its potential to spread the deadly Ebola disease.

Evidence-based recs issued for systemic care in psoriasis

Dec 19, 2014

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

Bacteria in caramel apples kills at least four in US

Dec 19, 2014

A listeria outbreak believed to originate from commercially packaged caramel apples has killed at least four people in the United States and sickened 28 people since November, officials said Friday.

Steroid-based treatment may answer needs of pediatric EoE patients

Dec 19, 2014

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.